When it comes to the current state of cancer survival, Susan Bates feels like many of the rest of us. "It's incredibly frustrating," she says. For Bates, who treats pancreatic and other cancers at ...

Protein systems make up the complex signaling pathways that control whether a cell divides or, in some cases, metastasizes. Ras proteins have long been the focus of cancer research because of their ...

Pancreatic cancer is extremely aggressive and often has a poor prognosis, so understanding the underlying molecular mechanism that keeps these particular cancer cells alive is critical to improving ...

RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in 2016 ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...

As a 10-year journey comes to fruition, MUSC Hollings Cancer Center researcher John O’Bryan, Ph.D., and colleagues have demonstrated a new therapeutic way to block a protein that is frequently mutated ...

K-Ras mutations are all too familiar as drivers of cancer. And until recently, they were considered all but undruggable. But ever since the arrival of sotorasib and adagrasib—two FDA-approved ...

Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor ...

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit Looks Back at Pancreatic Cancer in 2025: A Year of Progress, ...